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Abstract
Objective: The regulatory role of capsaicin-sensitive peptidergic sensory nerves has been shown in acute
inflammation, but little is known about their involvement in T/B-cell driven autoimmune arthritis. This study
integratively characterized the function of these nerve endings in the proteoglycan-induced chronic arthritis
(PGIA), a translational model of rheumatoid arthritis.
Methods: Peptidergic afferents were defunctionalized by resiniferatoxin (RTX) pretreatment in BALB/c mice,
PGIA was induced by repeated antigen challenges. Hind paw volume, arthritis severity, grasping ability and
the mechanonociceptive threshold were monitored during the 17-week experiment. Myeloperoxidase activity, vascular
leakage and bone turnover were evaluated by in vivo optical imaging. Bone morphology was assessed using micro-CT,
the intertarsal small joints were processed for histopathological analysis.
Results: Following desensitization of the capsaicin-sensitive afferents, ankle edema, arthritis severity and mechanical
hyperalgesia were markedly diminished. Myeloperoxidase activity was lower in the early, but increased in the late phase,
whilst plasma leakage and bone turnover were not altered. Desensitized mice displayed similar bone spurs and erosions,
but increased trabecular thickness of the tibia and bony ankylosis of the spine. Intertarsal cartilage thickness was
not altered in the model, but desensitization increased this parameter in both the non-arthritic and arthritic groups.
Conclusion: This is the first integrative in vivo functional and morphological characterization of the PGIA mouse model,
wherein peptidergic afferents have an important regulatory function. Their overall effect is proinflammatory by increasing
acute inflammation, immune cell activity and pain. Meanwhile, their activation decreases spinal ankylosis, arthritis-induced
altered trabecularity, and cartilage thickness in small joints.
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Introduction
Rheumatoid arthritis (RA) is the most prevalent autoin-
flammatory joint disease that results in a considerable bur-
den on both patients and society. There has been a great
improvement in the last two decades in its therapy, almost
exclusively due to the introduction of targeted monoclonal
antibodies [1]. In contrast, in the treatment of chronic,
severe pain, limited advances have been made. In chronic
pain conditions such as RA long-lasting analgesia and lack
of side effects are equally desirable, but most currently
available analgesics do not meet these criteria. Hence, it is
crucial to explore the complexity of the pathophysiological
mechanisms offering novel therapeutic approaches.
It is now established that neuro-immune interactions
play a critical role in not only pain and inflammation
[2, 3], but also in normal joint and bone homeostasis
[4]. Capsaicin-sensitive sensory nerves densely innerv-
ate joint capsule and the synovium, and they are crucial
for pain perception [5, 6]. These nerves are unique by
not only having the classical afferent functions, but they
also exert efferent activities [7]. This is orchestrated via
the release of multiple mediators, primarily neuropep-
tides. These nerve endings express transient receptor
potential vanilloid 1 (TRPV1) and ankyrin 1 (TRPA1)
receptors [8], which are activated and sensitized by nu-
merous exo- and endogenous agents, such as chemicals
(capsaicin, or resiniferatoxin; RTX), protons produced
in acidic tissue upon inflammation and various inflam-
matory mediators [9]. The activation results in the re-
lease of the aforementioned sensory neuropeptides,
including the proinflammatory tachykinins, calcitonin
gene-related peptide (CGRP), vasoactive intestinal poly-
peptide (VIP), and pituitary adenylate cyclase-activating
polypeptide (PACAP), that facilitate vasodilation and
immune cell recruitment (neurogenic inflammation).
Meanwhile, anti-inflammatory and analgesic neuropep-
tides like somatostatin are also simultaneously released
[10]. Numerous studies have proven that the dysregula-
tion of proinflammatory peptide levels occurs in joint
tissues and correlates with the severity of RA [11–15].
Moreover, it was also reported that abnormally high
levels of the anti-inflammatory somatostatin produced
by a somatostatinoma alleviated RA symptoms [16].
The cartilage proteoglycan (PG aggrecan)-induced
arthritis (PGIA) in BALB/c mice is a complex model of
RA, controlled by major histocompatibility complex
(MHC), T cell-dependent, and autoantibody-mediated
autoimmune disease [17, 18]. PGIA is a systemic model
affecting not only the joints of extremities, but also the
axial skeleton. The progression of the disease is also
comparable to that of the human condition. The initial
phase is characterized by acute inflammatory edema and
synovitis, which is followed by bone and cartilage re-
sorption, and it finally progresses into widespread
ankylosis of the joints. Furthermore, the multiple genetic
loci involved in the development of PGIA are syntenic
with the RA risk loci, as proven by genome-wide associ-
ation studies [19]. Type II collagen and PG are the major
components of the articular cartilage, the tissue which is
a target of cellular and humoral autoimmunity in RA
patients [20].
The concept of peripheral sensory-immune interactions
influencing autoinflammatory conditions was introduced
decades ago, but our understanding about its exact mech-
anism still remains fragmentary [21, 22]. We previously
demonstrated the crucial role of the capsaicin-sensitive
peptidergic afferets in the Complete Freund’s Adjuvant
(CFA)-, mast cell tryptase (MCT)-, and K/BxN serum-
transfer-induced arthritis models [2, 3, 23]. However, since
these models do not properly resemble the complex T and
B cell driven mechanism of RA, here we chose the PGIA
model, which is a more translational chronic model of RA
[24]. Our aims were (1) to characterize the model by
functional measurements of pain, joint mobility, and clin-
ical severity, and to follow the progression of the inflam-
mation and bone structure changes by non-invasive
imaging methods, as well as (2) to determine the role of




The experiments were performed according to European
legislation (Directive 2010/63/EU) and Hungarian
Government regulation (40/2013., II. 14.) of the protection
of animals used for scientific purposes. The studies were
approved by the Ethics Committee on Animal Research of
the University of Pécs according to the Ethical Codex of
Animal Experiments (license no: BA 02/2000–2/2012)
and complied with the recommendations of the Inter-
national Association for the Study of Pain. The human
sample collection was approved by the Institutional
Review Board of Rush University Medical Center,
Chicago, USA.
Animals and immunization
Experiments were performed on 8–12-week-old female
BALB/c mice. Animals were bred and maintained in
the animal facility of the Department of Immunology of
the University of Pécs, housed at 24–25 °C ambient
temperature, and provided with standard rodent chow
and water ad libitum under 12 h light/dark cycles.
PG was isolated, purified, and prepared for immunization
from human knee cartilages harvested during joint replace-
ment surgery. In brief, PG was extracted by 4M guani-
dinium chloride, centrifuged, partially deglycosylated,
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and purified as described [25]. BALB/c mice were im-
munized with 100 μg of core protein of PG in 100 μl
of phosphate-buffered saline (PBS; pH 7.4) [20], emulsified
with 2 mg of dimethyl-dioctadecyl ammonium brom-
ide (Sigma-Aldrich, St. Louis, MO, USA) in 100 μl of
PBS three times intraperitoneally (i.p.) at 3-week
intervals [26].
Resiniferatoxin pretreatment (desensitization)
Repeated pretreatment with RTX (Sigma-Aldrich; 30, 70,
100 μg/kg subcutaneously on 3 consecutive days), an
ultrapotent TRPV1 agonist induced a long-lasting defunc-
tionalization of the capsaicin-sensitive peptidergic affer-
ents [2, 3, 27]. A 1mg/ml stock solution was prepared,
which was further diluted with saline to 3, 7, and 10 μg/
ml. The volume of administration was 0.1 ml/10 g body
weight. 2 weeks after the last RTX administration, the suc-
cess of the desensitization was verified by the lack of
eye-wiping response to capsaicin drops (50 μl, 0.1%) [3].
Experimental design
Our measurements were carried out after the first i.p. PG
injection administered 2 weeks after RTX-pretreatment.
The mechanononiceptive threshold and the volume of the
hind paws were evaluated once a week from the 1st to the
12th week, neutrophil myeloperoxidase (MPO) activity,
and inflammatory vascular leakage were measured from the
6th to the 14th week. Arthritis severity and joint function
were assessed three times a week from 1st to the 16th week
of the study. Bone remodeling was assessed on week 13 of
the immunization, while micro-computed tomography
(micro-CT) was performed at the end of the 17-week
experiment. Following the micro-CT scans, the animals
were euthanized, and their ankle joints were removed for
histological processing (Additional file 1: Figure S1).
Assessment of disease severity and hind limb edema
The volume of the hind paws was measured weekly by
plethysmometry (Ugo Basile, Comerio, Italy) [2, 3]. Arth-
ritis severity and hyperemia were also evaluated semi-
quantitatively three times a week by visually scoring on a
scale of 0–4 for each limb (0, no edema or redness; 1,
mild edema of the distal paw or at least two digits; 2,
moderate swelling of the paw joints distal to the ankle
or wrist; 3, marked edema and hyperemia of the paw in-
cluding the ankle or wrist; 4, severe swelling and redness
of the entire paw with joint stiffness) [20, 26, 28]. All the
four extremities were scored by inspection and passive
moving of the joints; therefore, each mouse was scored
from 0 to 16.
Measurement of mechanonociception and joint function
The mechanonociceptive threshold of the hind paws was
measured weekly by dynamic plantar esthesiometry
(Ugo Basile). The maximum force was set to 10 g, and
the cut-off time was 4 s. Mechanical hyperalgesia was
expressed as the percent change compared to the pre-
treatment controls [2]. Joint function and grasping abil-
ity was assessed three times a week by placing the mice
on a horizontal wire mesh grid, which was consequently
turned over to determine the latency to fall [2]. The
cut-off time was 60 s. The percentage of mice which
were able to grasp the grid for the whole period of time
was plotted as a survival curve [29].
In vivo bioluminescent imaging of neutrophil MPO activity
Luminol is a chemiluminescent sensor of reactive oxygen
species (ROS) that mainly correlates with neutrophil
MPO-activity in vivo [30]. A 30mg/ml PBS solution of
luminol (GoldBio, St. Louis, MO, USA) was injected i.p. at
a dose of 150mg/kg. Animals were anesthetized using
ketamine (120mg/kg; Calypsol, Gedeon Richter, Budapest,
Hungary) and xylazine (6mg/kg; Sedaxylan, Eurovet Ani-
mal Health, Bladel, The Netherlands). Imaging was per-
formed 10min post injection using the IVIS Lumina II
optical imager (PerkinElmer, Waltham, USA) weekly
between the 6th and the 14th weeks of the experiment, as
neutrophil MPO-activity is predominantly increased dur-
ing the acute phase of inflammation. The acquisition time
was 120 s, F/stop = 1, and binning = 8. Regions of interest
(ROIs) were drawn corresponding to the hind limbs, in
which luminescence was expressed as total radiance (total
photon flux/s) [31].
In vivo fluorescent imaging of inflammatory vascular
leakage and bone turnover
Inflammatory vascular leakage was evaluated by intra-
venous (i.v.) injection of IR-676 (Spectrum-Info, Kyiv,
Ukraine), a vascular fluorescent dye, which was dissolved
in a 5w/v% aqueous solution of Kolliphor HS 15 (poly-
ethylene-glycol-15-hydroxystearate; Sigma-Aldrich) and
injected into anesthetized mice at a dose of 0.5 mg/kg.
Imaging was performed 20 min post injection using the
IVIS Lumina II in vivo imaging system (PerkinElmer).
Acquisition time was automatic, F/stop = 1, binning = 2,
excitation/emission filters were 640/700 nm. The ROIs
were applied to the ankle joints, in which fluorescence
was expressed as total radiant efficiency ([photons/s/
cm2/steradian/[μW/cm2]) [32].
Arthritic bone remodeling was assessed by OsteoSense
680 EX (PerkinElmer), a fluorescently labeled bisphos-
phonate in vivo imaging agent, which was injected i.v.
(2 nmol/subject) [33]. Measurements were performed
using the FMT 2000 fluorescence molecular tomography
system 24 h later (PerkinElmer). Three-dimensional (3D)
reconstructions of the region of the ankles were made,
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and ROIs were drawn, in which the amount of the fluor-
ophore was determined in picomoles. Since imaging the
spine with the FMT system is technically challenging,
bone remodeling in the vertebral column was measured
by the IVIS system. The imaging parameters were the fol-
lowing: auto acquisition time, F/Stop = 1, and binning = 2.
The excitation and emission filters were 640/700 nm. The
ROIs were applied as described earlier, and radiant
efficiency was expressed and used for further analysis.
In vivo micro-CT analysis of the ankles and lumbar spine
The right ankles and the lumbar spinal region were
repeatedly scanned using a 17.5 μm voxel size by a Sky-
Scan 1176 in vivo micro-CT (Bruker, Kontich, Belgium).
Changes of bone structure were assessed using the CT
Analyzer® software. ROIs of standard size were drawn
around the respective regions, in which bone volume
(μm3), bone surface (μm2), average thickness (mm) and
number (1/mm) of bone trabeculae, and the total
volume of bone pores (μm3) were calculated [2]. The
width of each lumbar intervertebral space was manually
measured at the ventral aspect of the spinal column
(μm), the means of which was used for further analysis.
Histological processing and assessment of cartilage thickness
The hind limbs of the mice of all the experimental
groups were fixed and then decalcified in a solution of
4% ethylenediaminetetraacetic acid (EDTA) for two
weeks. Samples were immersed into a pre-made rapid bone
decalcification solution (Decalc, HistoLab, Stockholm,
Sweden). Decalcified tissue samples were embedded into
paraffin, sectioned, and stained with a 0.1% aqueous
solution of dimethyl-methylene blue (DMMB) (Sigma-Al-
drich). Histological analysis was performed in a blinded
fashion. Representative photomicrographs were taken using
an Olympus DP72 camera on a Nikon Eclipse E800 micro-
scope (Nikon Corporation, Tokyo, Japan). Images were
acquired using CellSense Entry 1.5 software (Olympus,
Shinjuku, Tokyo, Japan).
Measurement of cartilage thickness was performed by
using Adobe Photoshop version 10.0 software. Since the
tibiotarsal joint underwent complete bony ankylosis in
both groups, the smaller intertarsal joint was selected
for evaluation of the articular cartilage. The average of
cartilage thicknesses in different experimental groups
were calculated and compared.
Statistics
Results are expressed as mean ± standard error of mean
(SEM). Statistical evaluation was performed by Graph-
Pad Prism®. Mechanical hyperalgesia, paw edema,
arthritis scores, the optical imaging of MPO activity, and
vascular leakage, as well as the micro-CT imaging of the
ankle were evaluated by repeated measures two-way
analysis of variance (ANOVA) and Bonferroni’s multiple
comparison test. In the case of mechanical hyperalgesia
and paw edema, percentage change values were com-
pared between treatment groups. In the case of the grid
test, percentage values were assessed by the log rank
test. Optical imaging of bone remodeling, the micro-CT
imaging of the lumbar spine, and the histological ana-
lysis of cartilage thickness were assessed by one-way
ANOVA and Tukey’s multiple comparison test. In all
cases, p < 0.05 was considered significant.
Results
Lack of capsaicin-sensitive nerves diminishes arthritic
mechanical hyperalgesia, but not grasping ability
The baseline mechanonociceptive threshold values of
the groups did not differ from each other (Add-
itional file 2: Table S1). Mechanical hyperalgesia
peaked between the 8th and the 11th week of the ex-
periment at 35% in non-desensitized and 20% in
desensitized arthritic mice, remaining significantly
lower in the latter group between the 6th and 11th
weeks of the experiment (Fig. 1a). Analyzing the per-
centage of animals which could stay on the horizontal
grid for 60 s, the grasping ability of non-desensitized
arthritic mice decreased until the 4th week, while in
the desensitized arthritic group, its decrease was ob-
served in the 2nd week. Despite the worsening joint
ankylosis, 50–60% of the arthritic mice could stay on
the grid for 30 s by week 4. However, a significant
difference was not seen between these groups (Fig. 1b).
The latency values of the grid test are shown in
Additional file 3: Table S2, and the results of the stat-
istical analysis in Additional file 4: Table S3.
Lack of capsaicin-sensitive nerves decreases arthritic
edema and inflammation severity score
Hind limb edema reached its peak during the 9th week.
The peak paw volume increase was 60% in
non-desensitized mice and significantly lower (40%) in
desensitized animals between the 7th and 9th weeks
(Fig. 1c). The arthritis severity score, also considering
limb stiffness and ankylosis increased gradually, and
was significantly lower in desensitized mice during the
8th to 10th weeks (Fig. 1d). The statistical analysis is
shown in Additional file 4: Table S3.
Lack of capsaicin-sensitive nerves bidirectionally alter
inflammatory MPO activity, but not vascular leakage and
bone turnover
ROS production peaked in the 7th week in non-
desensitized arthritic mice, and gradually decreased
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thereafter. In desensitized animals, MPO-activity was sig-
nificantly lower in the early phase, but remained relatively
steady thereafter, and was significantly higher in the 12th
week of the study (Fig. 2a–b). In non-desensitized mice,
vascular leakage reached its peak during the 9th week. In
desensitized mice, the inflammatory vascular permeability
increase was similar to that of their controls (Fig. 2c–d).
The statistical analysis is shown in Additional file 4:
Table S3. Bone remodeling in the 13th week increased
significantly in both the spine (Fig. 3a–b) and ankle joints
(Fig. 3c–d) of non-desensitized arthritic mice. In desensi-
tized animals, the bone turnover increase was only signifi-
cant in the ankle.
Lack of capsaicin-sensitive nerves increases trabecular
thickness of the bones of the arthritic ankle joint
By the 17th week of the experiment, a significant bone
volume loss of approximately 10% could be observed in
both non-desensitized and desensitized control mice
(Fig. 4a), due to the decreased density of the cortical
bone, also noticeable on the axial CT slices (Fig. 4d).
The bone density in arthritic mice remained un-
changed, and thus became significantly higher than in
the respective non-arthritic groups by the end of the
study, reflecting periarticular osteophyte formation
(Fig. 4c–d). The relative bone surface increased signifi-
cantly in both non-desensitized and desensitized arth-
ritic mice (Fig. 4a). This, coupled with the slightly but
significantly increased total pore volume (Fig. 4b), was
predominantly caused by inflammatory bone erosions,
which could be also observed on the 3D images
(Fig. 4c). The mean thickness of the bone trabeculae
decreased by 10–12% in the non-arthritic groups, while
it remained relatively unchanged in arthritic animals
(Fig. 4b). The trabecular thickness was significantly
higher only in desensitized arthritic group compared to
the desensitized control group.
Since the tibiotarsal joint underwent complete anky-
losis, cartilage could only be objectively assessed in the
smaller intertarsal joints at week 17, which were seem-
ingly not affected by the arthritis. However, in the desen-
sitized animals, regardless of the induction of PGIA, a
Fig. 1 Diminished mechanical hyperalgesia, edema, and arthritis severity score, but retained grasping ability after sensory desensitization. The changes of
the hind paw mechanonociceptive threshold (a), grasping ability (b), hind limb edema (c), and the semiquantitative arthritis severity score (d). Values are
the means ± SEM, n= 7–8/group. *p< 0.05, ***p< 0.001 vs. respective non-arthritic controls, #p< 0.05, ##p< 0.01, ###p< 0.001 vs. non-desensitized arthritic
mice. Grasping ability was assessed by log rank test, all other functional results by repeated measures two-way ANOVA
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significantly elevated thickness of the intertarsal cartilage
was found (Fig. 5a–b).
Lack of capsaicin-sensitive nerves increases bony
ankylosis in the arthritic spine
Non-desensitized and desensitized arthritic mice displayed
a similar decrease in spinal bone density and relative
surface by the 17th week of the experiment compared to
their respective controls (Fig. 6a). An increased total
porosity and a decreased density of bone trabeculae could
also be observed (Fig. 6b). The mean width of the lumbar
intervertebral spaces was significantly lower by approxi-
mately 40% in desensitized arthritic mice compared to
their non-desensitized controls (Fig. 6c). This was due to
the also visually apparent bony ankylosis (Fig. 6d).
Discussion
The current work presented two lines of novel data on
the PGIA mouse model of RA. The first was the com-
plex characterization of the different stages of the
chronic PGIA model of the mouse using integrative
methodologies. The PGIA model has been known as a
T cell-dependent chronic model of RA, mimicking
several molecular pathways of the human disease in-
cluding autoantibody-production and the cytokine
profile [20]. It is also known that ankylosis of the
affected joints occurs during the late phase, and both
the joints and the spine demonstrate evidence of sim-
ultaneous bone erosion and neoformation [17].
Although arthritic pain is a critical aspect of RA, noci-
ceptive responses have not been studied in this model.
Ours was the first study to show that PGIA induces a
long-lasting mechanical hyperalgesia, and thus it can
be suggested as an appropriate model of chronic arth-
ritic pain. A limitation of our study is that the nocifen-
sive behavior could not be investigated during the
total experimental period due to the ankylosis of the
ankle joint after the 3rd month. We also provided
compelling evidence of the complex effects of PGIA
on bone metabolism and architecture using novel
non-invasive imaging methods. Arthritic mice demon-
strate increased bone turnover in the hind paws,
coupled with the development of periarticular osteo-
phytes and erosions. The significant decrease in bone
Fig. 2 Lower MPO activity in the acute, but greater in the chronic phase of arthritis, without vascular leakage alterations after sensory desensitization.
Representative 2D bioluminescence images of MPO activity (a), and the quantification of the luminescence in the hind limbs (b). Representative 2D
fluorescence images of vascular leakage (c), and the quantitative evaluation of fluorescence (d). Values are the means ± SEM, n = 7–8/group. *p < 0.05,
**p < 0.01, ***p < 0.001 vs. respective non-arthritic controls, #p < 0.05, ##p < 0.01 vs. non-desensitized arthritic mice. Repeated measures two-way ANOVA
was used
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density in the control mice demonstrates the critical
importance of using age-matched controls in studies
investigating bone structural changes in RA models.
The other important novelty of our results is that
we provide the first evidence about the pivotal role of
the innervating capsaicin-sensitive sensory afferents in
the T and B lymphocyte-dependent disease-mimicking
model of RA. We showed that selective defunctionali-
zation of these nerves leads to decreased arthritis se-
verity, edema, and hyperalgesia. However, its effect on
neutrophil ROS production follows an interesting bi-
phasic pattern, demonstrated by MPO activity that is
lower in the early, but higher in the late phase of
arthritis. The functional implication of the late neu-
trophil activation is not clear as we did not see a cor-
responding worsening of functional parameters. On
the other hand, desensitization had no protective ef-
fect on the arthritis-induced changes in bone turnover
or bone morphometry.
The model induces a complete bony ankylosis of the
ankle joints, while the intertarsal small joints remain
undamaged. An unexpected result of our study was that
RTX defunctionalization increased cartilage thickness in
these joints. It has been demonstrated that peptidergic
sensory nerves penetrate the outer layers of articular
cartilage and modulate chondrocyte differentiation,
mainly via the release of calcitonin gene-related peptide
(CGRP) [4]. Thus, it can be speculated that the selective
deactivation of these fibers interferes with the homeosta-
sis of the articular cartilage.
Our present study demonstrated noteworthy differences
when compared to our earlier experiments using the
CFA-induced, K/BxN serum-transfer, and MCT models of
arthritis. In both the CFA-induced and serum-transfer
models, RTX-pretreatment aggravated arthritis severity
but reduced inflammatory hyperalgesia [2, 3]. However, in
the MCT model, joint hyperemia, and spontaneous pain
but not edema were diminished in desensitized animals
[23]. These essentially contradictory results of the earlier
and the current experiments are at least partly due to dis-
tinct mechanisms and therefore, the limited translational
value of the previously used models. For example,
although the CFA-induced rat arthritis model was origin-
ally described as a RA disease model, it has been proven
to rather model reactive arthritides with many features
not found in human RA [24, 34]. Arthritis in K/BxN mice
is triggered by autoreactive T cells and maintained by the
autoantibody production of B-cells, but serum-transfer
arthritis is a transient T/B-cell-independent model mim-
icking primarily the innate immune response to joint-spe-
cific autoantibodies [35, 36]. In a similar way, the MCT
model evoked solely by a mast-cell-specific protease
represents only one facet of the complexity of auto-
immune arthritis [37]. The PGIA model is the most trans-
lational RA model in term of adequately resembling all
aspects of the autoinflammatory response. In summary,
Fig. 3 Arthritic bone turnover increase is unaltered after sensory desensitization. Representative 2D epifluorescence images of the spine (a), and
the quantification of OsteoSense fluorescence (b). Representative 3D FMT reconstructions of the ankle joints (c) and the quantification of the amount of
fluorophore in picomols (d). Values are the means ± SEM, n= 5–6/group. **p< 0.01, ***p< 0.001 vs. respective non-arthritic control. One-way ANOVA was used
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Fig. 4 Increased trabecular thickness in the arthritic ankle joint, but unaltered bone spur formation and porosity after sensory desensitization. Changes in bone
volume and surface density (BV/TV, BS/TV) (a), trabecular thickness, and total pore volume (b). Representative 3D CT reconstructions of ankle joints (c) and axial
CT slices (d) demonstrating cortical bone loss and osteophyte formation (cortical irregularities highlighted by arrowheads). Values are the means ± SEM, n=7–
8/group. *p< 0.05, ***p< 0.001 vs. respective non-arthritic control, #p< 0.05, ##p< 0.01, ###p<0.001 vs. respective initial control. Two-way ANOVA was used
Fig. 5 Increased intertarsal cartilage thickness after sensory desensitization. Average thickness of cartilage (μm) (a). Representative photomicrographs of the
intertarsal joints (b). Values are the means ± SEM, n= 7–8/group, ###p< 0.001 vs. respective non-desensitized group. One-way ANOVA was used
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the observed differences highlight the importance of
desensitization in a T/B cell-driven arthritis model. Of
note, we cannot exclude that lymphocytes were directly
affected by the RTX treatment. The extraneural expres-
sion of TRP receptors has recently became a topic of
interest, and it has been proven that functional TRPV1 is
expressed on T (but not B) cells, contributing to their
pro-inflammatory response [38, 39]. On the other hand,
we have to mention that while the effect of desensitization
on TRPV1 present on T cells has not been addressed,
our own earlier studies involving other extraneural tis-
sues, such as skin or oral mucosa, failed to demon-
strate an effect of RTX-pretreatment on receptors
present in such tissues [40]. We have previously shown
that TRPV1 and TRPA1 gene-deficient mice show dimin-
ished inflammation, nociception, and histological damage
in CFA-induced model [41, 42]. Moreover, in the K/
BxN-serum transfer arthritis model reduced hyperalgesia
but increased edema was detected in TRPV1 gene-deleted
mice, while no differences were revealed in TRPA1 gene-
deficient animals [43]. These findings, taken together with
the current results indicate that TRP channel activation
aggravates local inflammation via the release of pro-in-
flammatory mediators, while it is also critical for inflam-
matory pain. Concerning a direct effect on the pain
component, it has to be pointed out that the involvement
of capsaicin-sensitive primary afferents in mechanonoci-
ception, mechanical hyperalgesia, and allodynia in models
of inflammatory, neuropathic, or cancer pain had been
extensively investigated. Several studies could not confirm
a role for this subpopulation of sensory neurons in mech-
anical hyperalgesia in contrast with thermal hyperalgesia
and spontaneous pain in these conditions [44–49], which
might be due to major differences in peripheral and cen-
tral sensitization mechanisms in these chronic patho-
physiological processes. However, in our long-lasting
Fig. 6 Increased bony ankylosis and unaltered spinal bone remodeling after sensory desensitization. Quantification of bone volume and surface
densities (BV/TV, BS/TV) (a), total pore volume and the number of trabeculae (b). Quantification of the mean intervertebral space, and representative
axial CT slices (c). Representative 3D reconstructions of the lumbar spine (d). Values are the means ± SEM, n = 7–8/group. **p < 0.01, ***p < 0.001 vs.
respective non-arthritic control. One-way ANOVA was used
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arthritis model with mixed inflammatory, neuropathic,
and degenerative mechanisms, we found a markedly
diminished mechanical hyperalgesia in desensitized arth-
ritic animals, which points to the feasibility of targeting
TRPV1 channels and TRPV1-expression sensory nerves
for analgesia at the periphery.
Previous studies have demonstrated the importance of
certain pro- and anti-inflammatory sensory neuropep-
tides in arthritis models [10, 31, 50], while the overall ef-
fect of sensory desensitization was found to be primarily
anti-inflammatory and analgesic in our current study.
The delayed decrease of MPO-activity has previously
also been observed in the K/BxN serum transfer model,
where mice deficient in PACAP, a major vasoactive pep-
tide mediator, showed a similarly increased neutrophil
ROS production in the late phase of arthritis [31].
The involvement of the axial skeleton is a unique
feature of PGIA, characterized by a robust spondyloar-
thropathy, syndesmophyte formation, and intervertebral
disc degeneration; hence it is also utilized as a model for
ankylosing spondylitis [51–53]. Our study demonstrated
narrowing of the intervertebral space, an indirect sign of
disc degeneration, is increased in desensitized arthritic
mice, while other aspects of bone structural changes are
similar to those of non-desensitized animals. This sug-
gests that peptidergic afferents have an overall protective
effect on PGIA-induced spondyloarthropathy.
Conclusions
It can be concluded that capsaicin-sensitive sensory
nerves play an important regulatory role in arthritic
pain and inflammation in the PGIA model of RA. The
impact of these afferents goes well beyond acute in-
flammation and nociception; they also have a complex
influence on the skeletal structural changes. Further
studies are needed to identify the specific key media-
tors released from these nerves, their targets and the
signaling pathways involved in the pathophysiological
mechanisms of the disease. Special emphasis should be
put on pain-related processes, since chronic arthritic pain
is still an unmet medical need. The pro-inflammatory and
algogenic functions of these afferents suggest that block-
ing these nerve terminals at the periphery might be a
promising treatment option.
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